AN \u3ci\u3eIN VITRO\u3c/i\u3e MICRO-VOLUME PROCEDURE FOR RAPID MEASUREMENT OF ERYTHROCYTIC HEXOSE MONOPHOSPHATE SHUNT ACTIVITY

I. A radiometric micro-volume procedure for measurement of erythrocytic hexose monophosphate shunt (HMS) activity in intact cells in vitro is described. 2.The procedure is rapid, allowing 200 individual HMS determinations in a single experiment of 5 hr duration. 3. The procedure is reproducible, yielding HMS activity means insignificantly different (P \u3e 0.05) between replicate experiments. 4. A profile of sodium nitrite-induced HMS stimulation is reported: HMS was elevated 2-fold (P \u3c 0.001) between zero and 2.5mM NaN02; HMS elevation was more distinct (7-fold) between 2.5 and 5.0mM NaNO2; maximum activity (22-fold) was observed between 10 and 20mM NaN02; \u3e 20mM NaNO2 caused significant (P \u3c 0.001) diminution of HMS; glucose carbon recycling through the HMS occurred only with \u3e 2.5mM NaNO2 where this process contributed :::; 16% to total HMS activity

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events